Brokers Offer Predictions for Inari Medical FY2027 Earnings

Inari Medical, Inc. (NASDAQ:NARI - Free Report) - Leerink Partnrs cut their FY2027 earnings estimates for shares of Inari Medical in a research note issued on Monday, November 25th. Leerink Partnrs analyst M. Kratky now expects that the company will post earnings of $0.54 per share for the year, down from their previous forecast of $0.56. Leerink Partnrs currently has a "Hold" rating on the stock. The consensus estimate for Inari Medical's current full-year earnings is ($0.77) per share. Leerink Partnrs also issued estimates for Inari Medical's FY2028 earnings at $0.97 EPS.

A number of other equities research analysts have also recently commented on the company. Needham & Company LLC restated a "hold" rating on shares of Inari Medical in a research report on Tuesday, October 29th. Leerink Partners initiated coverage on Inari Medical in a report on Tuesday, September 3rd. They issued a "market perform" rating and a $47.00 price objective on the stock. Piper Sandler upped their target price on Inari Medical from $50.00 to $52.00 and gave the stock a "neutral" rating in a research note on Tuesday, October 29th. Canaccord Genuity Group increased their target price on Inari Medical from $71.00 to $74.00 and gave the company a "buy" rating in a research report on Tuesday, October 29th. Finally, Wells Fargo & Company cut their price target on shares of Inari Medical from $84.00 to $65.00 and set an "overweight" rating for the company in a report on Wednesday, July 31st. Six investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $58.89.

Inari Medical Trading Up 2.7 %

NARI traded up $1.35 on Tuesday, reaching $50.83. The stock had a trading volume of 1,022,949 shares, compared to its average volume of 985,291. The business's 50-day moving average price is $45.73 and its two-hundred day moving average price is $47.38. The company has a market cap of $2.98 billion, a P/E ratio of -37.65 and a beta of 0.96. Inari Medical has a 12-month low of $36.73 and a 12-month high of $67.13.

Insider Activity

In other Inari Medical news, Director William Hoffman sold 60,000 shares of the business's stock in a transaction on Monday, November 18th. The stock was sold at an average price of $51.16, for a total transaction of $3,069,600.00. Following the transaction, the director now owns 501,233 shares of the company's stock, valued at approximately $25,643,080.28. The trade was a 10.69 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Mitch C. Hill sold 3,000 shares of the firm's stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $45.13, for a total value of $135,390.00. Following the completion of the sale, the chief financial officer now directly owns 179,600 shares of the company's stock, valued at $8,105,348. This trade represents a 1.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 186,000 shares of company stock worth $8,990,990 over the last three months. Insiders own 10.60% of the company's stock.

Institutional Investors Weigh In On Inari Medical

Hedge funds have recently modified their holdings of the company. GAMMA Investing LLC boosted its holdings in Inari Medical by 164.7% in the 2nd quarter. GAMMA Investing LLC now owns 704 shares of the company's stock valued at $34,000 after purchasing an additional 438 shares during the last quarter. Nisa Investment Advisors LLC lifted its holdings in Inari Medical by 83.5% in the second quarter. Nisa Investment Advisors LLC now owns 956 shares of the company's stock valued at $46,000 after acquiring an additional 435 shares during the last quarter. KBC Group NV grew its position in Inari Medical by 39.0% in the third quarter. KBC Group NV now owns 1,774 shares of the company's stock worth $73,000 after acquiring an additional 498 shares during the period. Benjamin F. Edwards & Company Inc. increased its stake in Inari Medical by 39.4% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company's stock worth $89,000 after acquiring an additional 522 shares during the last quarter. Finally, Covestor Ltd increased its position in shares of Inari Medical by 63.5% during the 3rd quarter. Covestor Ltd now owns 2,384 shares of the company's stock worth $99,000 after purchasing an additional 926 shares during the last quarter. Hedge funds and other institutional investors own 90.98% of the company's stock.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.